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ABSTRACT
Purpose: To compare morbidity, mortality, recurrence and 5-year survival between D1 and D2 or D3 for treatment of gastric cancer.
Methods: Systematic review and meta-analysis of RCTs. Metaview in RevMan 4.2.8 for analysis; statistical heterogeneity by Cochran’s
Q test (P<0.1) and I2 test (P>50%). Estimates of effect were calculated using random effects model. Results: D2 or D3 was associated
with higher in-hospital mortality, with RR = 2.13, p=0.0004, 95% CI, 1.40 to 3.25, I2=0%, P=0.63; overall morbidity showed higher
incidence in D2 or D3, RR = 1.98, p<0.00001, 95% CI, 1.64 to 2.38, I2 = 33.9%, P=0.20; operating time showed longer duration in D2
or D3, weighted mean difference of 1.05, p<0.00001, 95% CI, 0.71 to 1.38, I2 = 78.7%, P=0.03, with significant statistical heterogeneity;
reoperation showed higher rate in D2 or D3, with RR = 2.33, p<0.0001, 95% CI, 1.58 to 3.44, I2 = 0%, P=0.99; hospital stay showed
longer duration in the D2 or D3, with weighted mean difference of 4.72, p<0.00001, 95% CI, 3.80 to 5.65, I2 = 89.9%, P<0.00001;
recurrence was analyzed showed lower rate in D2 or D3, with RR = 0.89, p=0.02, 95% CI, 0.80 to 0.98, I2 = 71.0%, P = 0.03,
with significant statistical heterogeneity; mortality with recurrent disease showed higher incidence in D1, with RR = 0.88, p=0.04, 95%
CI, 0.78 to 0.99, I2 =51.8%, P=0.10; 5-year survival showed no significant difference, with RR = 1.05, p=0.40, 95% CI, 0.93 to 1.19,
I2 = 49.1% and P=0.12. Conclusions: D2 or D3 lymphadenectomy procedure is followed by higher overall morbidity and higher
in-hospital mortality; D2 or D3 lymphadenectomy shows lower incidence of recurrence and lower mortality with recurrent disease,
when analysed altogether with statistical heterogeneity; D2 or D3 lymphadenectomy has no significant impact on 5-year survival.
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RESUMO
Objetivo: Comparar a morbidade, mortalidade, recidiva e sobrevida de cinco anos entre linfadenectomia D1 e D2 ou D3 no tratamento
do câncer gástrico. Métodos: Revisão sistemática metanálise de ensaios clínicos randomizados, programa Metaview, Revman 4.2.8.
Heterogeneidade estatística pelo teste Q de Cochrane (P<0,1) e teste I2 (P>50%). Estimativas dos efeitos pelo modelo randômico.
Resultados: Maior mortalidade hospitalar em D2 ou D3, RR = 2.13, p=0.0004, 95% IC, 1.40 a 3.25, I2=0%, P=0.63; maior morbidade
geral em D2 ou D3, RR = 1.98, p<0.00001, 95% IC, 1.64 a 2.38, I2 = 33.9%, P=0.20; maior tempo operatório em D2 e D3, diferença de
média ponderal de 1.05, p<0.00001, 95% IC, 0.71 a 1.38, I2 = 78.7%, P=0.03; número de reoperações maior em D2 e D3, RR = 2.33,
p<0.0001, 95% IC, 1.58 a 3.44, I2 = 0%, P=0.99; maior tempo de permanência hospitalar em D2 e D3, diferença de média ponderal de
4.72, p<0.00001, 95% IC, 3.80 a 5.65, I2 = 89.9%, P<0.00001; recidiva maior nos grupos D2 e D3, RR = 0.89, p=0.02, 95% IC, 0.80 a
0.98, I2 = 71.0%, P = 0.03; mortalidade com doença recidivada maior em D1, RR = 0.88, p=0.04, 95% IC, 0.78 a 0.99, I2 =51.8%,
P=0.10; 5 anos de sobrevida mostrou diferença estatística não significante, RR = 1.05, p=0.40, 95% IC, 0.93 a 1.19, I2 = 49.1% e P=0.12.
Conclusões: Linfadenectomia D2 ou D3 está associada a maior morbidade e maior mortalidade intra-hospitalar; D2 ou D3 apresenta
menor incidência de recidiva e menor mortalidade com recidiva, analisadas em conjunto, com heterogeneidade estatística; D2 ou D3 não
tem impacto na sobrevida de 5 anos.
Descritores: Neoplasias Gástricas. Excisão de Linfonodo. Metanálise. Ensaio Clínico. Prognóstico.
1Research performed at Clinical Epidemiology Division, University Center of Volta Redonda (UNIFOA), Brazilian Cochrane Center, Division of
Surgical Gastroenterological, Department of Surgery, Federal University of Sao Paulo (UNIFESP), Brazil.
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Introduction
Many aspects of the results from surgical treatment of
gastric cancer remain controversial. Several observational studies
have reported potential benefits from extended lymphadenectomy
in terms of recurrence and 5-year survival, but randomized
controlled trials have failed to confirm these results1,2,3,4,5. The
theoretical advantage in extended lymph node resection, such
that it increases the chances for curative treatment, might be
illusory if it is considered that these nodes may not be involved
in the disease. Moreover, by extending the node dissection, the
surgical treatment may substantially increase the morbidity and
mortality6,7,8.
Therefore the presumed therapeutic benefit of extended
lymphadenectomy remains to be proven and a systematic review
and meta-analysis of homogeneous randomized controlled trials
could give the answer in terms of the best available scientific
evidence so far. We undertook this study in order to analyze the
existing evidence and to provide a meta-analysis of morbidity,
mortality, recurrence and 5-year survival parameters.
Methods
The logistics and the design for this study were prepared
according to Cochrane Collaboration methodology and
approved by the UNIFESP-Escola Paulista de Medicina
Cochrane Meta-analysis Unit, Sao Paulo, Brazil. The writing
and interpreting of reports for this systematic review was based
on the Quality of Reporting of Meta-analysis (QUORUM)
group statement, using a 17-item checklist for reporting
systematic reviews9.
Search strategy for identification of studies
The following bibliographic databases were searched in
order to identify randomized controlled trials (RCTs): Cochrane
Central Register of Controlled Trials, MEDLINE, EMBASE,
LILACS, Science Citation Index and Ovid journals. The references
of the RCTs identified were checked to complete the electronic
searches, without limitation on date or language. Abstracts of
possibly relevant papers were identified and, after reaching a
consensus in the reviewers’ analysis, such articles were retrieved
in full.
The search strategy in Medline (PubMed) was based
on medical subject heading terms (MeSH), text words and
Boolean operators such as ‘AND’, ‘OR’ and ‘NOT’, which
were used in succession; the following subject terms with
appropriate combinations were used: Search 1 - dissection,
nodal dissection, resection, r1 gastrectomy, r2 gastrectomy,
d1 dissection, d2 dissection, d3 dissection, r3 gastrectomy
and lymphadenectomy; Search 2 – gastric neoplasms, gastric
carcinoma, gastric cancer and stomach neoplasms; Search 3 –
randomized controlled trials, controlled clinical trials, double-
blind methods, placebos, research design, comparative study,
evaluation studies, follow-up studies, prospective studies,
animals and cross-over studies; Search 4 – search 1, 2 and 3.
A cross-reference search for review articles in leading journals
was conducted.
Study selection and data extraction
All RCTs comparing D1 vs. D2 and D1 vs. D3 were
included for evaluation of methodological quality. Data were
extracted using a pre-designed form. The methodological quality
of the studies was assessed on the basis of pre-specified
characteristics: the method of the research, the participants, the
standardization of the interventions, the outcome measurements
and the standardization of pathological examinations. The
randomization procedure was analyzed in terms of the method
used to generate the random allocation sequence, the explanation
of the allocation concealment and the method of implementing
the allocation sequence10.
Each trial was assessed by two reviewers (SASL and
DM), independently and without blinding, in order to evaluate
whether the trial should be included or not. Disagreements were
resolved by consensus. The basis for the methodological evaluation
was the randomization procedure, sample size calculation,
description of the eligibility criteria, intention-to-treat analysis,
standardization of the surgical procedure and standardization
of pathological examination. The data on the included and
excluded studies were extracted and detailed in tables. The
clinical heterogeneity between the included studies was discussed
by all authors of this systematic review.
Analysis
Statistical analysis were carried out by entering the
extracted data into Metaview in RevMan 4.2.8 software
(Cochrane Collaboration, Oxford, UK) and the relative risk
(RR) or weighted mean difference (WMD) was calculated
for each outcome. When the model assumed that there was no
heterogeneity between individual trials, fixed effects models
(Mantel-Haenszel and Peto methods) were used. If statistical
heterogeneity was incorporated, a random effects model
(DerSimonian-Laird method) was used11.
The degree of statistical homogeneity between the
s tudies  was  assessed  by  us ing  the  modif ied  ʠ2 t es t
(Cochran’s Q) which, by convention, indicates the presence
of heterogeneity when P>0.1. When a small number of trials
were included in the meta-analysis the I2 test was used, which
is considered statistically significant if 50% or greater.
A cutoff of p<0.05 was required for the overall relative
risk (RR) or weighted mean difference (WMD) to be deemed
statistically significant. Results relating to intervention effects
were presented using forest plot graphs. Number needed to harm
(NNH) was calculated and sensitivity analysis adjusted for
methodological quality was performed.
The sensitivity analysis was done by excluding or
including studies that appeared to be outliers. If studies
seemed to be heavily affecting the results they were excluded
and the analysis was repeated without them.
Results
Included studies
All RCTs published as original studies, citing D1 versus
D2 or D1 versus D3 lymphadenectomy as a primary treatment for
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gastric cancer with curative intent, up to the end of May 2007,
were considered. Special attention was given to systematic
review and meta-analysis with the same objective. Abstracts
were not included.
The systematic electronic search of the literature
identified 51 abstracts, which were subjected to a screening
process resulting in 9 full articles; 4 of these articles did not
fulfill the inclusion criteria, which made it possible to select
5 randomized controlled trials (9 reports). Three trials12,13,14
were national multicenter studies from the Netherlands, UK
and Italy respectively; two studies5,15 were done at single
institutions in China and Taiwan respectively.
Three of the selected trials compared D1 vs. D212,13,14
and two trials compared D1 vs. D35,15. These studies involved
1549 patients, of whom 791 were allocated to the D1 surgical
procedure, 617 to D2 and 141 to D3.
A systematic review was conducted by McCulloch
et al.6, in 2005, including randomized and non-randomized
comparisons between D1 and D2 gastrectomy for primary
treatment of gastric cancer. The meta-analysis was performed
separately;15 separate studies were selected, comprising two
randomized trials, two non-randomized comparisons and 11
cohort studies reporting results from one technique only.
The  main  s tudy charac ter i s t ics  and  i tems of
methodological quality, outcome measurements and sample
sizes of the included studies are shown in Table1.
TABLE 1 - Characteristics of the RCTs included in the review
JRSGC – Japanese Society for Research in Gastric Cancer UICC – International Union Against Cancer
RCT – Randomized controlled trials
STUDY REFERENCE AIM METHODOLOGICAL QUALITY OUTCOMES Sample 
Size 
ROBERTSON, 1994 
 
 
D1 x D3 RANDOMIZATION PROCEDURE          Adequate 
SAMPLE SIZE CALCULATION               - 
ELEGIBILITY CRITERIA DESCRIBED   YES 
INTENTION-TO-TREAT ANALYSIS        -                   
SURGERY STANDARDIZATION            YES 
PATHOLOGIC STANDARDIZATION      YES 
STAGE OF DISEASE                              T1, T2, T3, T4 
SURGEON EXPERIENCE                       YES 
OVERALL MORBIDITY 
IN-HOSPITAL MORTALITY 
MORTALITY WITH 
RECURRENCE 
INTRA-ABDOMINAL 
INFECTION 
HOSPITAL STAY 
OPERATING TIME 
REOPERATION 
5-YEAR SURVIVAL 
D1 = 25 
D3 = 30 
 
CUSCHIERI, 1996, 1999 
 
 
D1 X D2 
 
RANDOMIZATION PROCEDURE           Adequate 
SAMPLE SIZE CALCULATION              YES 
ELEGIBILITY CRITERIA DESCRIBED   YES 
INTENTION-TO-TREAT ANALYSIS       YES 
SURGERY STANDARDIZATION            JRSCG 
PATHOLOGIC STANDARDIZATION      UICC 
STAGE OF DISEASE                              T1, T2, T3 
SURGEON EXPERIENCE                       - 
 
OVERALL MORBIDITY 
IN-HOSPITAL MORTALITY 
MORTALITY WITH 
RECURRENCE 
CARDIAC MORBIDITY 
PULMONARY MORBIDITY 
TROMBOEMBOLIC 
MORBIDITY 
HOSPITAL STAY 
RECURRENCE 
5-YEAR SURVIVAL 
 
D1 = 200 
D2 = 200 
 
BONENKAMP,1995,1999 
 
 
D1 x D2 
 
RANDOMIZATION PROCEDURE           Adequate 
SAMPLE SIZE CALCULATION               YES 
ELEGIBILITY CRITERIA DESCRIBED    YES 
INTENTION-TO-TREAT ANALYSIS        YES 
SURGERY STANDARDIZATION            JRSGC 
PATHOLOGIC STANDARDIZATION      JRSGC 
STAGE OF DISEASE                            T1,T2,T3,T4,Tx 
SURGEONS EXPERIENCE                     YES 
 
OVERALL MORBIDITY 
IN-HOSPITAL MORTALITY 
MORTALITY WITH 
RECURRENCE 
WOUND INFECTION 
INTRA-ABDOMINAL 
INFECTION 
PANCREATIC LEAKAGE 
ANASTOMOTIC LEAKAGE 
CARDIAC MORBIDITY 
PULMONARY MORBIDITY 
TROMBOEMBOLIC 
MORBIDITY 
REOPERATION 
HOSPITAL STAY 
RECURRENCE 
5-YEAR SURVIVAL 
 
D1 = 380 
D2 = 331 
 
 
DEGIULI, 1998 
 
D1 x D2 
 
RANDOMIZATION PROCEDURE            Adequate 
SAMPLE SIZE CALCULATION               YES 
ELEGIBILITY CRITERIA DESCRIBED    YES                  
INTENTION-TO-TREAT ANALYSIS         - 
SURGERY STANDARDIZATION             JRSGC 
PATHOLOGIC STANDARDIZATION       JRSGC 
STAGE OF DISEASE                                T1, T2, T3 
SURGEON EXPERIENCE                         YES 
 
OVERALL MORBIDITY 
IN-HOSPITAL MORTALITY 
INTRA-ABDOMINAL 
INFECTION 
PANCREATIC LEAKAGE 
CARDIAC MORBIDITY 
PULMONARY MORBIDITY 
REOPERATION 
HOSPITAL STAY 
 
D1 = 76 
D2 = 86     
 
 
WU, 2004, 2006 
 
 
D1 x D3 
 
RANDOMIZATION PROCEDURE            Adequate 
SAMPLE SIZE CALCULATION               YES 
ELEGIBILITY CRITERIA DESCRIBED    YES 
INTENTION-TO-TREAT ANALYSIS         - 
SURGERY STANDARDIZATION             JRSGC 
PATHOLOGIC STANDARDIZATION      JRSGC 
STAGE OF DISEASE                              T1, T2, T3, T4 
SURGEON EXPERIENCE                        YES 
 
OVERALL MORBIDITY 
IN-HOSPITAL MORTALITY 
MORTALITY WITH 
RECURRENCE 
WOUND INFECTION 
INTRA-ABDOMINAL 
INFECTION 
PANCREATIC LEAKAGE 
ANASTOMOTIC LEAKAGE 
CARDIAC MORBIDITY 
OPERATING TIME 
REOPERATION 
HOSPITAL STAY 
5-YEAR SURVIVAL 
 
 
D1 = 110    
D3 = 111 
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Methodological quality of the included studies
The randomization procedure was described in all the
included studies. It was regarded as very good in all trials except
one5, in which it was considered adequate since this trial did not
explain the method used for implementing the random allocation
and whether the allocation concealment was maintained until the
interventions were assigned.
The underlying sample size calculation was described in
four studies, while one trial5 did not justify how the number of
patients that entered the study was determined. In the Dutch trial12,
the calculated sample size was based on an expected five-year
survival rate of 20% for patients undergoing D1 dissection with
curative intent and 32% for those undergoing surgery with D2
dissection with curative intent; in the Chinese trial17 the sample
size calculation was based on an expected 5-year survival rate
of 20% with D1 dissection and 40% for those allocated to D3
dissection (Wu 2006); in the Italian trial14 the size of the study was
calculated on the basis of the effects on 5-year survival rate, from
30% after D1 to 45% after D2 surgery; in the UK trial3 the sample
size was calculated based on a improvement of 5-year survival from
20% in the D1 procedure to 34% in the D2 procedure.
The eligibility criteria for participants and the settings were
described in all trials. Eligible patients had to have histologically
proven gastric adenocarcinoma that was potentially curable, and
physical fitness suitable for elective operation of either type of
lymphadenectomy. The upper age limit for entering the studies was
variable, ranging from 75 to 85 years4,17. Patients with esophageal
involvement, previous chemotherapy or radiotherapy or previous
coexisting cancer were excluded. In all trials the patient was
finally eligible to enter the trial when, in the staging laparotomy,
the tumor could be excised and if a safe margin for radical subtotal
or total gastrectomy could be obtained. Biopsies and frozen
sections of enlarged lymph nodes were obtained in the staging
laparotomy in 4 trials3,4,14,15. The analysis of the outcome
All the surgeons involved in four included trials3,4,14,15  were
trained and supervised the procedures. The quality control was well
described in 4 trials3,4,5,14, in which the participating surgeons had
been specially trained for D2 dissection and for supervising
the technique and the extent of lymph-node dissection; after
the operation, the perigastric tissue was divided into the proper
lymph-node stations and the number and location of nodes were
detected at pathological examination in accordance with the
protocol guidelines4.
Excluded studies
Only one randomized controlled trial was excluded from
this systematic review for not fulfilling the inclusion criteria. This
excluded study which was published in 1988 reported 3 years of
follow-up time8.
Meta-analysis results
In-hospital mortality
In-hospital mortality, which was analyzed in 5 studies
that included 1549 patients, of whom 617 D2 vs 656 D1 and 141
D3 vs 135 D1 patients, showed a significantly higher rate in the
D2 (RR, 2.12; 95% CI, 1.39 to 3.25; p=0.0005) with no significant
statistical data heterogeneity (P = 0.42, I2 = 0%) and a not significant
difference in the D3 lymphadenectomy group (RR, 2.52; CI, 95%,
0.11 to 59.18; p=0.57)5,12,13,14,15.
The overall effect estimate of 758 D2/D3 versus 791
D1 patients revealed significantly higher in-hospital mortality
rate (RR, 2.13; 95% CI, 1.40 to 3.25; p=0.0004) with no
significant statistical data heterogeneity (P=0.63 and I2 =0%).
The meta-analysis result from this outcome measurement is
shown in Figure 1.
FIGURE 1 – Meta-analysis of in-hospital mortality rate. Effects estimates (odds ratio; 95% CI). Pooled
treatment effect is shown as a diamond that spans the 95% CI. No statistical heterogeneity between studies
results. Overall effect with significant statistical difference favouring D1 lymphadenectomy (p=0,00004)
measurements was performed on
an intention-to-treat basis in only
two trials3,4.
The JRSCG (Japanese
Society for Research in Gastric
Cancer) provided guidelines for
the standardization of surgical
treatment in 4 trials3,4,14,15 and
standardization of pathological
evaluation in 3 trials3,4,14. The
UICC (International Union
Against Cancer) provided the
pathological standardization in
one tr ial3.  In one tr ial 5 the
operative procedures and the
processing of the specimens
were described but no reference
was reported.
With regard to disease
staging, two trials included
patients in the T1, T2 and T3
pathological stages3,15 and three
trials included patients in the T1,
T2, T3 and T4 pathological
stages3,4,5.
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Overall morbidity
Overall morbidity,
which was analyzed in 5 studies
that included 1549 patients, of
whom 617 D2 vs 656 D1 and
141 D3 vs 135 D1 patients,
showed both a significantly
higher rate in the D2 (RR, 1.83;
95%CI, 1.51 to 2.21;p<0.00001)
w i t h  n o  s t a t i s t i c a l  d a t a
heterogeneity (P = 0.46, I2 = 0%)
and in the D3 lymphadenectomy
group (RR, 4.07; 95% CI, 1.96
t o  8 . 4 3 ;  p = 0 . 0 0 0 2 )  w i t h
statistical data heterogeneity
(P = 0.05, I2 = 74%).
The  overa l l  e ffec t
estimate of 758 D2/D3 versus
791 D1 pa t ien ts  revea led
significantly higher overall
morbidity rate (RR, 1.98; 95%
CI; 1.64 to 2.38, p<0.00001) with
no significant statistical data
heterogeneity (P=0.20 and
I2 =33.9%). The meta-analysis
resu l t  f rom th i s  ou tcome
measurement  i s  shown in
Figure 2.
FIGURE 2 – Meta-analysis of overall morbidity. Effects estimates (odds ratio; 95% CI). Pooled treatment
effect is shown as a diamond that spans the 95% CI. No statistical heterogeneity between D1 x D2 studies
results. Overall effect with significant statistical difference favouring D1 lymphadenectomy (p<0,00001)
TABLE 2 – Summary of the meta-analysis results of morbidity parameters
Outcome Measures Studies Sample Size Statistical 
Method 
Effect Size Heterogeneity p value 
 
Anastomotic 
Leakage 
 
Bonenkamp 1995 
Wu 2004 
 
D1=490 
 
D2 or D3=442 
 
RR (fixed) 
 
CI 95% 
 
 
2.44 (1.38, 4.31) 
    
   P = 0.27 
   I
2 
= 17,3% 
 
 
0,002* 
Favours D1 
Wound Infection Bonenkamp 1995 
Wu 2004 
 
D1=490 
 
D2 or D3=442 
RR(fixed) 
 
CI 95% 
 
 
2.32 (1.32, 4.08) 
P = 0.93 
I
2 
= 0 % 
0,003* 
Favours D1 
Intra-abdominal 
infection 
Bonenkamp 1995 
Robertson 1994 
De Giuli 2004 
Wu 2004 
 
D1=591 
 
D2 or D3=558 
RR (fixed) 
 
CI 95% 
 
2.84 (1.91, 4.23) 
 
P = 0,11 
    I
2 
= 50,5%* 
0,00001* 
Favours D1 
Cardiac Morbidity Robertson 1994 
Bonenkamp 1995 
Cushieri 1996 
De Giuli 2004 
Wu 2004 
 
D1=766 
 
D2 or D3=728 
RR (fixed) 
 
CI 95% 
 
1.55 (o.87, 2.75) 
 
I
2 
= 18,8% 
P = 0.30 
0,14 
 
Pulmonary 
Morbidity 
Bonenkamp 1995 
Cushieri 1996 
De Giuli 2004 
Wu 2004 
 
D1=656 
 
D2 or D3=617 
RR (fixed) 
 
CI 95% 
 
2.25 (1.48, 3.42 
 
I
2 
= 0 % 
P = 0.75 
0,0002* 
Favours D1 
Trombo-Embolic 
Morbidity 
Bonenkamp 1995 
Cushieri 1996 
D1=580 
 
D2 or D3=531 
RR (fixed) 
 
CI 95% 
 
 
2.96 (0.80, 11.00) 
 
   I
2 
= 0 % 
  P = 0.39 
0,10 
Morbidity parameters
The results for all the morbidity parameters analyzed favored D1 over D2 or D3
lymphadenectomy, with a statistically significant difference, except for thromboembolic
mortality. The summary of the meta-analysis results relating to the morbidity parameters
of wound infection, intra-abdominal infection, anastomotic leakage, cardiac morbidity,
pulmonary morbidity and thromboembolic morbidity are shown in Table 2.
RR = Relative risk CI = Confidence interval I2 = Heterogeneity  index
P = Heterogeneity index p =  test for overall effect * = statistically significant
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Operating time, reoperation and hospital stay
Operating time, which was analyzed in 2 studies that
included 276 patients, of whom 30 D2 vs 25 D1 and 111 D3
vs 110 D1 patients, showed both a significantly higher rate
in the D2 (WMD, 2.00; 95%CI, 1.07 to 2.93) and in the D3
lymphadenectomy group (WMD, 1.05; 95% CI, 0.54 to 1.26)5,15.
The overall effect estimate of 141 D2/D3 versus 135 D1
patients revealed significantly longer operating time (WMD, 1.05;
95% CI; 0.71 to 1.38, p<0.00001) with significant statistical data
heterogeneity (P=0.03 and I2 =78.7%). The meta-analysis result
from this outcome measurement is shown in Figure 3.
FIGURE 3 – Meta-analysis of operating time (hours). Effects estimates (odds ratio; 95% CI). Pooled treatment effect is
shown as a diamond that spans the 95% CI. Significant statistical heterogeneity between studies results. Overall effect
with significant statistically signigicant difference between D1 and D3 lymphadenectomy favoring D1 (p<0,00001)
Reoperation rate, which was analyzed in 4 studies  that
included 1149 patients, of whom 417 D2 vs 456 D1 and 141 D3
vs 135 D1 patients, showed a significantly higher rate in the D2
(RR, 2.27; 95%CI, 1.51 to 3.41;p<0.0001) with no statistical data
heterogeneity (P = 0.89, I2 = 0%) and a no significant difference
in the D3 lymphadenectomy group (RR, 2.93; 95% CI, 0.76
to 11.21; p=0.12) with no statistical data heterogeneity (P = 0.99,
I2 = 0%)5,12,13,15.
The overall effect estimate of 558 D2/D3 versus 591
D1 patients revealed significantly higher in-hospital reoperation
rate (RR, 2.33; 95% CI; 1.58 to 3.44, p<0.0001) with no
significant statistical data heterogeneity (P=0.99 and I2 = 0%).
The meta-analysis result from this outcome measurement is
shown in Figure 4.
FIGURE 4 – Meta-analysis of reoperation. Effects estimates (odds ratio; 95% CI). Pooled treatment effect is shown as
a diamond that spans the 95% CI. No significant statistical heterogeneity between studies results. Overall effect with
statistically significant difference between D1 and D2 or D3 lymphadenectomy favoring D1 (p<0.0001)
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Hospital stay, which was analyzed in 5 studies that
included 1548 patients, of whom 617 D2 vs 655 D1 and 141 D3
vs 135 D1 patients, showed both a significantly higher rate in the
D2 (WMD, 4.38; 95%CI, 3.34 to 5.42;p<0.00001) with statistical
data heterogeneity (P< 0.00001, I2 = 94.3%) and a significantly
higher difference in the D3 lymphadenectomy group (WMD, 6.04;
95% CI, 4.00 to 8.09; p< 0,00001) with statistical data heterogeneity
(P = 0.11, I2 = 61.6%)5,12,13,14,15.
The overall effect estimate of 758 D2/D3 versus 790 D1
patients revealed significantly longer hospital stay (WMD, 4.72;
95% CI; 3.80 to 5.65, p<0.00001) with significant statistical data
heterogeneity (P< 0,00001 and I2 = 89.9%). The meta-analysis
result from this outcome measurement is shown in Figure 5.
FIGURE 5 – Meta-analysis of hospital stay (days). Effects estimates (odds ratio; 95% CI). Pooled treatment effect is
shown as a diamond that spans the 95% CI. Significant statistical heterogeneity between studies results. Overall effect
with statistically significant difference between D1 and D2 or D3 lymphadenectomy favoring D1 (p=0.00001)
Recurrence
Recurrence rate, which was analyzed in 3 studies that
included 1332 patients, of whom 531 D2 vs 580 D1 and 111 D3
vs 110 D1 patients, showed a no significant difference in the D2
(RR, 0.91; 95%CI, 0.82 to 1.01;p=0.08) with statistical data
heterogeneity (P = 0.03, I2 = 78.8%) and a no significant difference
in the D3 lymphadenectomy group (RR, 0.76; 95% CI, 0.57 to
11.21; p=1.02)5, 12,15.
The overall effect estimate of 642 D2/D3 versus 690 D1
patients revealed significantly higher recurrence rate in the D1
lymphadenectomy group (RR, 0.89; 95% CI; 0.80 to 0.98, p<0.02)
with significant statistical data heterogeneity (P=0.03 and I2 = 71%).
The meta-analysis result from this outcome measurement is
shown in Figure 6.
FIGURE 6 – Meta-analysis of recurrence. Effects estimates (odds ratio; 95% CI). Pooled treatment effect is shown
as a diamond that spans the 95% CI. Significant statistical heterogeneity between studies results. Overall effect with
statistically significant difference favoring D2 or D3 lymphadenectomy (p=0.02)
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Mortality with recurrent disease
Mortality with recurrent disease, which was analyzed in 4
studies  that included 1387 patients, of whom 531 D2 vs 580 D1
and 141 D3 vs 135 D1 patients, showed a no significant difference
in the D2 (RR, 0.89; 95%CI, 0.77 to 1.01;p=0.08) with statistical
data heterogeneity (P = 0.14, I2 = 54.8%) and a no significant
difference in the D3 lymphadenectomy group (RR, 0.83; 95% CI,
FIGURE 7 – Meta-analysis of mortality with recurrence. Effects estimates (odds ratio; 95% CI). Pooled treatment
effect is shown as a diamond that spans the 95% CI. Significant statistical heterogeneity between studies results.
Overall effect with statistically significant difference favoring D2 or D3 lymphadenectomy (p=0.04)
5-year survival rate
5-year survival rate, which
was analyzed in 4 studies  that
included 1387 patients, of whom
531 D2 vs 580 D1 and 141 D3 vs
135 D1 patients,  showed a no
significant higher difference in the
D2 (RR, 1.00; 95%CI, 0.87 to
1.16;p<0.97) with no statistical data
heterogeneity (P = 0.34, I2 = 0%)
and a no significant difference in the
D3 lymphadenectomy group (RR,
1.24; 95% CI, 0.98 to 1.56; p=0.08)
with  statistical data heterogeneity
(P = 0.07, I2 = 68.9%)5,12,13,15.
The overall effect estimate of
672 D2/D3 versus 715 D1 patients
revealed no significant 5-year survival
rate (RR, 1.05; 95% CI; 0.93 to 1.19,
p=0.40) with no significant statistical
data heterogeneity (P=0.12 and I2 =
49.1%). The meta-analysis result from
this outcome measurement is shown
in Figure 8.
0.62 to 1.12; p=0.23) with  statistical data heterogeneity (P = 0.06,
I2 = 72.8%)5,12,13,15.
The overall effect estimate of 672 D2/D3 versus 715
D1 patients revealed significantly higher mortality with recurrent
disease rate (RR, 0.88; 95% CI; 0.78 to 0.99, p=0.04) with
significant statistical data heterogeneity (P=0.10 and I2 = 51.8%).
The meta-analysis result from this outcome measurement is
shown in Figure 7.
FIGURE 8 – Meta-analysis of 5-year survival. Effects estimates (odds ratio; 95% CI). Pooled treatment
effect is shown as a diamond that spans the 95% CI. No significant statistical heterogeneity between
studies results. Overall effect with no statistically significant difference between D1 and D2 or D3
lymphadenectomy (p=0.40)
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Discussion
Systematic review and meta-analysis provide an accurate
scientific tool for screening the best available evidence in the
medical literature, but  methodological quality of the primary
studies is essential in order to obtain reliable conclusions about
the overall effect of the interventions. To avoid distortions we
decided only to accept the results from studies with clinical and
statistical homogeneity.
One possible source of bias could lie in the differences
between the randomization processes in the included studies.
However, the quality of the allocation procedure was regarded as
very good in all studies but one, in which the randomization
procedure was considered adequate. All the patients analyzed had
definite eligibility criteria. In the statistical analysis, the sample
size calculation and intention-to-treat rule were used. Standard
definitions for outcome parameters, standardization of surgical
procedures and standardization of pathological examinations were
described in all studies.
When we compared participants’ characteristics between
the studies, we noted that there was an adequate balance
between the TNM I, II and III groups that underwent D1 versus
D2 or D3 lymphadenectomy. However, clinical heterogeneity
between studies may have been a source of bias, with the
inclusion of a small number of patients with TNM staging IV
and X in two studies5,15.
We decided to use the random effects model to calculate
the meta-analysis, considering the possible implicit sources of
clinical and methodological heterogeneity between the studies, and
also because this provides wider confidence intervals, which are
therefore thought to be more realistic.
The literature search strategy implemented showed that
very few randomized controlled trials comparing the results
between D1 and D2 or D3 lymphadenectomy for gastric cancer are
available. Even though no clear benefit has so far been shown,
some investigators have pursued a supposed optimum extent
of surgical intervention, as in the recently reported evaluation
of the possible benefits of extended D2(+) para-aortic
lymphadenectomy in patients with potentially curatively
resected gastric cancer18,19,20,21,22,23,24.
The clinical trials by the UK Surgical Cooperative Group3
and the Dutch Gastric Cancer Study Group4 showed high rates of
postoperative morbidity and mortality, which may have negatively
affected the outcome measurements of safety and efficacy18. In
fact, the results from these meta-analysis have confirmed that the
findings from those trials concerning morbidity and mortality can
be formally accepted. The notion that mortality rates have been
greatly reduced, based on the results from recent clinical trials on
the surgical treatment of gastric cancer and that extended lymph
node resection can be performed safely in experienced centers is
unlikely to be valid6,14,16,17,19.
Because of the complexity of extended lymphadenectomy,
substantial morbidity and mortality has to be expected, even when
the procedure is done by well-trained and experienced surgeons
who work in hospitals that treat many patients with gastric
cancer17. In order to minimize the morbidity and mortality rate,
other factors involved, such as the patients’ ages, general physical
condition, comorbidities, operation time and tumor stage, cannot
be disregarded.
Analysis of the subset of results from the Surgical
Cooperative Group3 and Dutch Gastric Cancer Group4 trials
indicates that the higher morbidity in the D2 group is due not to
the extended lymphadenectomy but largely to pancreatic resection
and splenectomy. Thus, the possible reasons for the adverse effects
of pancreaticosplenectomy could be subclinical leakage of
pancreatic juice, vascular impairment of the stomach remnant
following proximal ligature of the arterial pedicles, and extensive
clearance of tissue and lymph nodes in the gastric bed13. The
question that remains is if the complications related to removal
of the spleen and pancreas are excluded is there a real difference
in morbidity/mortality from the D2 dissection. Unfortunately  these
data are not available for analysis.
The increased morbidity and mortality rates preclude
the association of pancreatectomy to D2 lymphadenectomy,
unless there is local involvement of the pancreas. Preserving
the spleen in order to avoid increasing the incidence of morbidity
and mortality leads to insufficient clearance of the lymph nodes
along the distal splenic artery and splenic hilum in patients
with proximal tumors3. Some authors have emphasized that
pancreatic resection should be done in gastric cancer cases with
local involvement and splenectomy only for proximal gastric
tumors1,18.
Our meta-analysis results showed that D2 or D3
lymphadenectomy has a statistically significant relative risk
of in-hospital mortality of 2.13, when compared with D1
lymphadenectomy, in five randomized clinical trials with no
clinical and statistical heterogeneity that address this question
and are of good methodological quality5,12,13,14,15.
Likewise, our meta-analysis results also showed also
that D2 or D3 lymphadenectomy has a statistically significant
relative risk of 1.98 of overall morbidity, when compared to D1
lymphadenectomy, in five randomized clinical trials with no
clinical and statistical heterogeneity that address this question
and are of good methodological quality5,13,14,15.
Concerning quantitative outcome measurements related
to the operating time, number of reoperations and length of
hospital stay, the meta-analysis results showed statistically
s ignif icant  di fferences  in  a l l  ra tes ,  favoring the D1
lymphadenectomy procedure. The overall morbidity data
were consistent with these meta-analysis results for these
continuous outcome measurements.
If it is considered that in the west world approximately
half of the patients treated by curative gastrectomy will die from
residual or recurrent local disease extended lymphadenectomy
for treating gastric cancer could be a rational policy, since
theoretically it could lead to reduction of bed recurrence by
locally controlling the cancer5,25. However, the clinical trials of the
UK Surgical Cooperative Group3 and the Dutch Gastric Cancer
Study Group4 failed to show any improvement in the postoperative
recurrence rates when D1 and D2 lymphadenectomy were
compared. In these trials, there was a tendency towards lower
cumulative risk of relapse after D2 dissection, but the rate of
relapse remained high.
In our study, the meta-analysis of recurrence rate was
calculated based only on three randomized controlled trials, two3,4,
comparing D1 vs. D2 and one12 comparing D1 vs. D3. Although
a significantly higher difference between the recurrence rates
was found after the D1 procedure when compared to D2 or D3,
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there is a great deal of statistical heterogeneity in the studies.
Furthermore, the results from D1 vs. D3 are based on a small
number of events that were analyzed in just one study that also
failed to show any statistically significant difference in the
recurrence rates between the groups. Under these circumstances
the meta-analysis results must be interpreted with cautiousness.
Similarly, the mortality rate due to recurrence was significantly
higher in the D1 lymphadenectomy group, but with significant
statistical heterogeneity among the data of 4 randomized
controlled trials4,5,12,13.
Based on the results from our meta-analysis, the overall
effect for 5-year survival rate did not show any statistically
significant difference when D1 was compared to D2 or D3
lymphadenectomy, using data from 4 studies with no significant
statistical heterogeneity among them. In contrast with the trials
from the UK, Netherlands and Hong Kong, in 2006, showed that
D3 lymphadenectomy had a significant long-term survival benefit
over D1 lymphadenectomy, by comparing 111 and 110 patients
respectively with each treatment4,5,12,13.  The same authors had
shown previously that D3 lymphadenectomy can be performed
with acceptable morbidity. These results must also be interpreted
cautiously and, unless patients are selected and included properly
in randomized controlled trials, these results should not be accepted
in general practice.
The question posed by Bonenkamp et al.12, in 1995, i.e.
whether extended D2 lymphadenectomy with postoperative
morbidity and mortality rates twice those of the standard D1
lymphadenectomy technique should be accepted as general
practice, if no long-term benefit in survival rate has been
demonstrated, cannot be answered yet due to lack of good
scientific evidence on this specific issue.
Overall survival rates after radical gastric cancer
surgical treatment from Western and Japanese institutions differ
substantially. As reported in the literature, the migration of the
disease into a more advanced stage by demonstrating lymph
nodes metastases that remain unidentified when conventional
surgical treatment and pathologic techniques are applied,
significantly affects the nodal staging26. Recent randomized
clinical trials have demonstrated confounding effects related
to extended lymphadenectomy on stage-specific and overall
survival. As systematic extended lymph nodes dissection induces
important staging migration, the presumed benefits of extended
lymphadenectomy, in terms of survival rates, still remains to be
evaluated26,27.
The real  oncological  benef i ts  f rom extended
lymphadenectomy for treating gastric cancer, concerning
recurrence and 5-year survival, still has to be proven. For the
time being, we not only have to give importance to experience as a
result of sustained caseload, surgical skill and case selection but
also have to accept that extended lymphadenectomy may only be
advantageous for surgical treatment of gastric cancer if morbidity
and mortality rates can be reduced7,28. Wang et al.29 concluded that
D2 dissection yields higher postoperative morbidity and mortality
than D1 dissection and that standard D3 dissection can increase
the overall survival when compared to D1 dissection and if
splenectomy or pancreaticosplenectomy cases are involved D2
dissection can only improve the survival rate of T3 staged patients.
For gastric cancer the Japanese Research Society for
the Study of Gastric Cancer (JRSGC) has strongly recommended
extended lymphadenectomy, although it is still unclear, in terms of
high level scientific evidence, whether this procedure improves
survival or merely refines staging4. A recent reported clinical trial,
at 24 japanese hospitals, comparing D2 lymphadenectomy alone
with D2 procedure with para-aortic nodal dissection for gastric
cancer, has shown that no improvement in the survival rate has
been obtained30.
In the West patient fitness for surgery and patient obesity
can prevent even the most experienced surgeons from achieving
optimal lymph node dissection. Thus when a safe D2 dissection
cannot be expected due to any of these factors adjuvant
chemoradiotherapy might prove an adequate substitute. Different
combinations of treatment should be established for each clinical
circumstance and surgeons should play a key role here31.
This critical literature review has shown us that extended
lymphadenectomy for surgical treatment of gastric cancer has a
high cost in terms of morbidity and mortality and that it is not as
successful in oncological terms as it has been presumed, when
compared to the standard D1 lymphadenectomy technique.
High-quality randomized clinical trials from specialized centers
addressing this issue are still needed.
Conclusions
O u r  f i n d i n g s  i n d i c a t e  t h a t  t h e  D 2  o r  D 3
lymphadenectomy procedure for primary treatment of gastric
cancer is followed by significantly higher overall morbidity and
significantly higher in-hospital mortality than is the D1 standard
technique; extended D2 or D3 lymphadenectomy shows
significantly lower incidence of recurrence and lower mortality
with recurrent disease, when analysed altogether (D1 x D2 or D3),
in comparison with D1 nodal dissection, but these results are based
on studies with statistical heterogeneity; extended D2 or D3
lymphadenectomy has no significant impact on 5-year survival rate.
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